- Home
- NRIX
as 07-26-2024 4:00pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 926.4M | IPO Year: | 2020 |
| Target Price: | $25.82 | AVG Volume (30 days): | 975.1K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.22 - $24.38 | Next Earning Date: | 07-11-2024 |
| Revenue: | $62,303,000 | Revenue Growth: | 2.25% |
| Revenue Growth (this year): | -3.35% | Revenue Growth (next year): | -7.26% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Jul 1 '24 | Sell | $21.57 | 801 | $17,277.33 | 19,838 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Jul 1 '24 | Sell | $20.68 | 4,959 | $102,559.56 | 20,639 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Jun 20 '24 | Sell | $20.01 | 20,000 | $400,216.00 | 48,333 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Jun 13 '24 | Sell | $17.02 | 1,864 | $31,721.18 | 19,838 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Jun 12 '24 | Sell | $17.01 | 1,900 | $32,319.00 | 19,838 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Jun 5 '24 | Sell | $17.00 | 400 | $6,801.00 | 19,838 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Jun 3 '24 | Sell | $17.01 | 1,596 | $27,152.91 | 19,838 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | May 2 '24 | Sell | $12.83 | 3,499 | $44,878.17 | 68,333 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Apr 30 '24 | Sell | $12.04 | 1,513 | $18,219.85 | 19,838 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Apr 30 '24 | Sell | $12.04 | 1,387 | $16,702.53 | 71,832 | SEC Form 4 |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Apr 30 '24 | Sell | $12.04 | 2,007 | $24,168.70 | 39,601 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Feb 16 '24 | Sell | $10.02 | 6,812 | $68,222.86 | 68,333 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Jan 30 '24 | Sell | $7.99 | 1,671 | $13,351.62 | 75,145 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Jan 30 '24 | Sell | $7.99 | 1,760 | $14,062.75 | 17,427 | SEC Form 4 |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Jan 30 '24 | Sell | $7.99 | 2,334 | $18,649.13 | 36,402 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Dec 20 '23 | Sell | $10.00 | 3,541 | $35,420.98 | 71,930 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Dec 19 '23 | Sell | $10.00 | 10,906 | $109,092.72 | 75,471 | SEC Form 4 |
| van Houte Hans | NRIX | Chief Financial Officer | Oct 30 '23 | Sell | $5.20 | 1,080 | $5,613.19 | 86,377 | SEC Form 4 |
| Ring Christine | NRIX | Chief Legal Officer | Oct 30 '23 | Sell | $5.20 | 1,232 | $6,403.20 | 15,263 | SEC Form 4 |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Oct 30 '23 | Sell | $5.20 | 1,633 | $8,487.35 | 33,529 | SEC Form 4 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
Zacks
10 days ago
Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
MT Newswires
11 days ago
Barclays Adjusts Price Target on Nurix Therapeutics to $31 From $20, Maintains Overweight Rating
MT Newswires
11 days ago
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating
MT Newswires
14 days ago
Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating
MT Newswires
15 days ago
RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk
Zacks
15 days ago
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
MT Newswires
15 days ago
Nurix Therapeutics Q2 Loss Widens Amid Revenue Decline
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.